JP2023548632A5 - - Google Patents

Info

Publication number
JP2023548632A5
JP2023548632A5 JP2023535666A JP2023535666A JP2023548632A5 JP 2023548632 A5 JP2023548632 A5 JP 2023548632A5 JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023548632 A5 JP2023548632 A5 JP 2023548632A5
Authority
JP
Japan
Prior art keywords
fusion protein
dnaj
tau
aav
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056539 external-priority patent/WO2022093736A1/en
Publication of JP2023548632A publication Critical patent/JP2023548632A/ja
Publication of JP2023548632A5 publication Critical patent/JP2023548632A5/ja
Pending legal-status Critical Current

Links

JP2023535666A 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法 Pending JP2023548632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105,472 2020-10-26
PCT/US2021/056539 WO2022093736A1 (en) 2020-10-26 2021-10-26 Compositions and methods for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2023548632A JP2023548632A (ja) 2023-11-17
JP2023548632A5 true JP2023548632A5 (cg-RX-API-DMAC7.html) 2024-10-30

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535666A Pending JP2023548632A (ja) 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法

Country Status (8)

Country Link
US (1) US20240025954A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232462A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548632A (cg-RX-API-DMAC7.html)
CN (1) CN117098771A (cg-RX-API-DMAC7.html)
AU (1) AU2021367952A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199433A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233655A (cg-RX-API-DMAC7.html)
WO (1) WO2022093736A1 (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
CN1440420A (zh) 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
WO2019161386A1 (en) 2018-02-19 2019-08-22 New York University Alpha-synuclein single domain antibodies
GB201902392D0 (en) * 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
JP2023520927A (ja) * 2020-04-10 2023-05-22 ソラ・バイオサイエンシズ・エルエルシー タンパク質凝集障害の処置のための組成物および方法
JP7894321B2 (ja) * 2020-04-28 2026-07-23 ソラ・バイオサイエンシズ・エルエルシー Tdp-43プロテイノパチーの処置のための組成物および方法

Similar Documents

Publication Publication Date Title
JP2023524414A5 (cg-RX-API-DMAC7.html)
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP2023504314A5 (cg-RX-API-DMAC7.html)
US20240060054A9 (en) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
JP2020072703A5 (cg-RX-API-DMAC7.html)
EP3256574B1 (en) Recombinant adeno-associated virus particle purification comprising an affinity purification step
ES2230569T3 (es) Funciones accesorias para uso en la produccion de viriones aav recombinantes.
JP6042825B2 (ja) 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
JP2020505936A5 (cg-RX-API-DMAC7.html)
JP5704361B2 (ja) 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
JP2009526067A5 (cg-RX-API-DMAC7.html)
JP2019001805A5 (cg-RX-API-DMAC7.html)
JP2017536116A5 (cg-RX-API-DMAC7.html)
JP2025518706A (ja) Aavカプシドバリアント及びその使用
US20170067028A1 (en) Radiolabeling of adeno associated virus
JP2023529371A5 (cg-RX-API-DMAC7.html)
JP2020533959A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2023506030A5 (cg-RX-API-DMAC7.html)
JP7558535B2 (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
TW201704253A (zh) 殼體
JP2017510298A5 (cg-RX-API-DMAC7.html)
JP7142643B2 (ja) Hdac阻害剤またはrepタンパク質を伴う細胞培養方法
JP2022066336A5 (cg-RX-API-DMAC7.html)
Bello et al. Isolation and evaluation of novel adeno-associated virus sequences from porcine tissues